Introduction
============

Cholangiocarcinoma (CCA) is a biliary malignancy which originates in the bile duct epithelium and can be subclassified according to the location as intrahepatic, extrahepatic or perihilar ([@b1-ol-0-0-10852]--[@b3-ol-0-0-10852]). Although rare, the incidence of CCA has increased in the past decade ([@b2-ol-0-0-10852],[@b3-ol-0-0-10852]). CCA is prone to lymphatic metastasis and has a high mortality rate. CCA may be difficult to diagnose until advanced stages of the disease. The majority of patients with CCA are diagnosed at an advanced stage of the disease, when loco-regional invasion or distant metastasis has occurred ([@b2-ol-0-0-10852],[@b3-ol-0-0-10852]). Curative surgical intervention for patients in an early stage is unlikely ([@b2-ol-0-0-10852]). Although the diagnostic methods for CCA have improved, several patients with CCA face delayed or inaccurate diagnoses, resulting in a decreased five-year overall survival time ([@b3-ol-0-0-10852]). This suggests that novel biomarkers for the early diagnosis of CCA as well as specific targeted therapy are required to improve patient outcomes in CCA.

Next generation RNA sequencing technology has revealed the complexity and diversity of the human genome ([@b4-ol-0-0-10852]). Non-coding RNAs (ncRNAs) constitute the majority of the transcriptome and include microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circle-RNAs ([@b4-ol-0-0-10852]--[@b6-ol-0-0-10852]). ncRNAs are involved in several important biological functions, such as RNA transcription and intracellular and intercellular communication ([@b4-ol-0-0-10852]). Furthermore, lncRNAs may serve as novel biomarkers and drug targets, in different types of cancer, including renal, breast and prostate cancer ([@b5-ol-0-0-10852],[@b6-ol-0-0-10852]). However, the mechanism by which lncRNAs regulate the expression of genes remains unclear.

Salmena *et al* ([@b7-ol-0-0-10852]) proposed the competing endogenous RNA (ceRNA) hypothesis, which suggest that lncRNAs may act as ceRNAs to suppress miRNA function by sharing one or more miRNA response elements. This hypothesis has since been supported by a number of studies ([@b8-ol-0-0-10852],[@b9-ol-0-0-10852]). lncRNAs may modulate genes at the protein-coding level and take part in the regulation of cellular processes by competing with miRNAs ([@b10-ol-0-0-10852],[@b11-ol-0-0-10852]). The importance of the lncRNA-miRNA-mRNA regulatory network in tumor pathogenesis and progression has been demonstrated in numerous studies ([@b12-ol-0-0-10852]--[@b14-ol-0-0-10852]). However, the role of the ceRNA network in CCA has not been elucidated and requires further investigation.

Weighted gene co-expression network analysis (WGCNA) is a novel systems biology method for describing the correlation patterns among genes across microarray samples ([@b15-ol-0-0-10852],[@b16-ol-0-0-10852]). WGCNA may be used to identify modules of highly related genes, to summarize such clusters using eigengenes or intramodular hub genes, to associate modules to one another and to external sample traits, and to calculate module membership measures ([@b17-ol-0-0-10852],[@b18-ol-0-0-10852]). Correlation networks may be applied to network-based gene screening methods that can be used to identify candidate biomarkers or therapeutic targets ([@b17-ol-0-0-10852]--[@b19-ol-0-0-10852]). The present study performed WGCNA and multiple database analyses to construct a ceRNA network to elucidate the interactions between differentially expressed (DE) lncRNAs, DEmiRNAs and DEmRNAs in CCA.

Materials and methods
=====================

### Study population

A total of 45 CCA samples were used in a comprehensive integrated analysis, including 36 samples from patients and 9 from healthy controls. The dataset was downloaded from the The Cancer Genome Atlas database (TCGA; [cancergenome.nih.gov](cancergenome.nih.gov)) using the Genomics Data Commons Data Transfer Tool, release number 16.0 ([gdc.cancer.gov/access-data/gdc-data-transfer-tool](gdc.cancer.gov/access-data/gdc-data-transfer-tool)). The data included a level three gene expression file of mRNAseq and miRNAseq data as well as patient clinical information. The current study met the publication guidelines provided by TCGA ([cancergenome.nih.gov/publications/publicationguidelines](cancergenome.nih.gov/publications/publicationguidelines)).

### Differential expression analysis

The mRNAseq data used in the current study were derived from 45 samples, including 36 CCA samples (tumor cohort) and 9 normal tissue samples that were extracted from adjacent tissues (normal cohort). The data from the two types of samples were merged and the data points that were close to zero were removed. The 'DESeq' package ([www.bioconductor.org/packages/DESeq](www.bioconductor.org/packages/DESeq))in R software version 3.5.2 ([www.r-project.org](www.r-project.org)) was used to identify the DEmRNAs and DEmiRNAs. A threshold of \|log2 fold change (FC)\|\>2.0 and an adjusted P\<0.01 were used to select the DEmRNAs and DEmiRNAs. The Encyclopedia of DNA Elements ([www.encodeproject.org](www.encodeproject.org)) was used to define and annotate the lncRNAs. The DElncRNAs with cut-off criteria of \|log2 FC\|\>2.0 and an adjusted P\<0.01 were selected. To remove any potential noise, the FC values associated with the comparisons that were not considered significant by the 'limma' package ([www.bioconductor.org/packages/limma](www.bioconductor.org/packages/limma)) or potentially significant by threshold-filtering were converted to 'zero', where the log2 scale corresponded with the complete absence of differential regulation among all samples. In addition, the GeneCards database (<https://www.genecards.org/>) was used for annotation, as it is a searchable, integrative database that provides comprehensive information on all annotated human genes.

### Weighted gene co-expression network construction and functional annotation

WGCNA, a systematic biology method, describes the co-expression patterns between genes across microarray samples. WGCNA can be used for identifying modules of highly correlated genes, for summarizing these clusters using the module eigengene or an intramodular hub gene, for relating modules to one another and to external sample traits, and for calculating module membership measures. Co-expression networks facilitate network-based gene screening methods that can be used to identify candidate biomarkers or therapeutic targets ([@b18-ol-0-0-10852]). Therefore, to identify the interactions between the differentially expressed genes (DEGs), the 'WGCNA' package ([www.bioconductor.org/packages/WGCNA](www.bioconductor.org/packages/WGCNA)) in R software was used to identify co-expression modules, with a power cut-off threshold of four and a minimum module size limited to 20 in the present study.

In order to confirm Kyoto Encyclopedia of Genes and Genomes (KEGG; genome.jp/kegg) pathways of DEGs, the 'cluster profiler' package ([www.bioconductor.org/packages/clusterprofiler](www.bioconductor.org/packages/clusterprofiler)) in R software was used to annotate the function of the different module genes. The Search Tool for the Retrieval of Interacting Genes (STRING; [www.string-db.org](www.string-db.org)) was subsequently used to evaluate the protein-protein interaction (PPI) network for the different colored modules, and Cytoscape software 3.2.0 (<https://cytoscape.org/>) was used to construct the PPI network.

### Construction of the ceRNA network

To investigate the association between lncRNA and miRNA in the ceRNA network, a coexpression network of DEmRNA, DEmiRNA and DElncRNA and was constructed using Cytoscape software. The pairs of miRNA-mRNA were selected using miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw>) ([@b20-ol-0-0-10852]). The data in miRTarBase has been verified by various methods, including the reporter assay, reverse transcription quantitative PCR, western blotting, microarray and next-generation sequencing experiments. Furthermore, the lncRNA-miRNA interactions were assessed using the miRcode database ([www.mircode.org](www.mircode.org)), which includes \>10,000 lncRNA genes ([@b21-ol-0-0-10852]).

### Survival and co-expression analysis

The clinical data of patients with CCA were used to identify the prognostic DE RNA signatures and a multivariate Cox proportional hazard regression analysis was performed. The regression coefficient of each gene was determined using the 'survival' package ([www.bioconductor.org/packages/surival](www.bioconductor.org/packages/surival)) in R software. The coefficient of each selected gene presented the estimated logarithm of the hazard ratio. The risk score formula was used to define the high- and low-risk groups. The Kaplan-Meier method was used to assess the survival time difference between two groups using the log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

### Pearson\'s correlation coefficient analysis

The Pearson\'s correlation coefficient was used to identify the correlations between DElncRNAs and DEmRNAs involved in the established ceRNA network. P\<0.01 and R\>0.5 were used to indicate a statistically significant difference.

Results
=======

### Identification of DEmRNAs, DEmiRNAs and DElncRNAs

The clinical information of the patients from whom the 36 CCA samples were obtained is presented in [Table I](#tI-ol-0-0-10852){ref-type="table"}. Using the 'DESeq' package in R software, 1,095 DEmRNAs and 75 DEmiRNAs were identified. The results obtained in the current study indicated that there were 862 (78.72%) upregulated and 233 (21.28%) downregulated DEmRNAs. In addition, a total of 70 upregulated and 5 downregulated DEmiRNAs were identified. Furthermore, a total of 485 aberrantly expressed lncRNAs in CCA tissues compared with normal tissues were identified using the GeneCards database The heatmap clustering of DEmRNAs, DEmiRNAs and DElncRNA is presented in [Figs. S1](#SD1-ol-0-0-10852){ref-type="supplementary-material"}--[3](#SD1-ol-0-0-10852){ref-type="supplementary-material"}.

### Construction of weighted gene co-expression modules

In order to identify the functional clusters in patients with CCA, the gene co-expression network analysis of 1,095 DEmRNAs was performed by WGCNA. As illustrated in [Fig. 1](#f1-ol-0-0-10852){ref-type="fig"}, six color modules were clustered, while the non-clustering DEmRNAs were presented in grey. Each branch in the dendrogram signified a single gene. The area occupied by each color illustrated the number of genes within the corresponding module.

### PPI and functional annotation for the modules

Using the STRING tool, 4 PPI networks were identified in the modules, including turquoise, blue, brown and yellow modules. However, a relevant PPI was not identified in the green module. Additionally, in order to identify the function and PPI of DEmRNAs in the different colored modules, KEGG pathway annotation for each module was performed and is presented in [Table II](#tII-ol-0-0-10852){ref-type="table"}. Hub DEmRNAs from the PPI networks were selected for ceRNA network construction. As illustrated in [Fig. 2](#f2-ol-0-0-10852){ref-type="fig"}, the relevant modules (turquoise, blue, brown and yellow) were selected for visualization of the Cytoscape software results.

### Construction of the ceRNA network in CCA

To further explore the association between lncRNAs and miRNAs in patients with CCA, a ceRNA network was constructed using the three types of DE RNAs. DEmiRNA-mRNA pairs were predicted using the miRTarBase database. A total of 12 hub DEmRNAs were identified as targeted genes by WGCNA. These were LRRK2, TBC1D2, E2F1, SHISA6, CYP1B1, TMEM100, PCDHAC2, GRIK3, FOXQ1, PCDHA1, HOXC13 and SALL3. DEmiRNAs, including hsa-mir-519d, hsa-mir-31, hsa-mir-506, hsa-mir-372, hsa-mir-373, hsa-mir-144, hsa-mir-205, hsa-mir-221, hsa-mir-222, hsa-mir-187, hsa-mir-375 and hsa-mir-184, were subsequently identified to be closely associated with the aforementioned 12 hub DEmRNAs. A total of 30 DElncRNAs that were also closely associated with the DEmiRNAs were identified using the miRcode database ([Table III](#tIII-ol-0-0-10852){ref-type="table"}). The DEmiRNAs and lncRNAs in the ceRNA network are presented in [Table IV](#tIV-ol-0-0-10852){ref-type="table"}. Two highly clustered DElncRNAs in the ceRNA network were identified, AC022148.1 and OPCML intronic transcript 1 (OPCML-IT1). AC022148.1 interacted with hsa-mir-372, hsa-mir-373, hsa-mir-144, hsa-mir-519d, hsa-mir-205, hsa-mir-221, hsa-mir-222 and hsa-mir-31. OPCML-IT1 interacted closely with 7 miRNAs, including hsa-mir-372, hsa-mir-373, hsa-mir-519d, hsa-mir-184, hsa-mir-205, hsa-mir-506 and hsa-mir-375. The ceRNA network is presented in [Fig. 3](#f3-ol-0-0-10852){ref-type="fig"}.

### Survival and correlation analysis for the hub DEmRNAs, DEmiRNAs and DElncRNAs

A total of 12 DEmRNAs, 12 DEmiRNAs and 30 DElncRNAs were identified as hub genes in the tumorigenesis of CCA. To explore the effect these RNAs had on the overall survival time, Kaplan-Meier curve analysis was used to obtain a prognostic signature. Survival analysis in [Fig. 4](#f4-ol-0-0-10852){ref-type="fig"} revealed that two key mRNAs, SALL3 and E2F1, were associated with the progression of CCA. High SALL3 mRNA expression, but low E2F1 expression were associated with poor prognosis. Additionally, low expression levels of hsa-mir-144 and hsa-mir-184 were also associated with poor prognosis. MIR181A2HG and OPCML-IT1 had positive effects on the overall survival time of patients with CCA. Pearson\'s correlation coefficient analysis revealed that OPCML-IT1 has a stronger correlation with SALL3 in [Fig. 5](#f5-ol-0-0-10852){ref-type="fig"}.

Discussion
==========

With a high mortality and an increasing incidence rate globally, the mechanisms underlying CCA are currently being investigated ([@b1-ol-0-0-10852]--[@b3-ol-0-0-10852]). Numerous studies have revealed that dysregulated miRNAs and lncRNAs may be involved in tumor progression ([@b22-ol-0-0-10852]--[@b24-ol-0-0-10852]). Previous studies have demonstrated that non-coding RNAs may serve an important role in various biological processes ([@b4-ol-0-0-10852],[@b24-ol-0-0-10852]--[@b28-ol-0-0-10852]). The ceRNA network has been implicated in a number of different types of cancer and may contribute to tumor progression and metastasis in triple negative breast cancer ([@b25-ol-0-0-10852]), papillary renal cell carcinoma ([@b26-ol-0-0-10852]) and gastric cancer ([@b27-ol-0-0-10852]). A previous study revealed that two key ceRNA clusters involved in cell-based functions may contribute to CCA ([@b28-ol-0-0-10852]). However, the specific lncRNAs involved in the overall survival time in CCA remain unclear. The current study therefore comprehensively integrated mRNA and miRNA data from TCGA and constructed a ceRNA network of lncRNA-miRNA-mRNA interactions to further explore the mechanism of lncRNAs in CCA.

In the current study, 30 DElncRNAs were identified as the hub lncRNAs which were involved in the ceRNA network. MIR181A2HG and OPCML-IT1 were revealed to be potential prognostic biomarkers for CCA. As illustrated in the ceRNA network, these two DElncRNAs had more interactions and were involved in regulating the target genes by competing for a common miRNA (mir-205).

lncRNAs are non-protein-coding transcripts consisting of \>200 nucleotides and have been revealed to regulate cellular processes ([@b29-ol-0-0-10852]). MIR181A2HG is the host gene of MIR181A2, and its overexpression has been associated with several types of cancer. Xu *et al* ([@b30-ol-0-0-10852]) demonstrated that MIR181A2HG was downregulated by estrogen in breast cancer. A previous study demonstrated that MIR181A2HG was upregulated in elderly patients with breast cancer ([@b31-ol-0-0-10852]).

The current study revealed that high expression of MIR181A2HG may compete with one key DEmiRNA (mir-205) to mediate the expression of target genes. In addition, patients with highly expressed MIR181A2HG had shorter survival time compared with those with low expression according to the survival analysis performed in the current study. OPCML-IT1, another hub DElncRNA in the ceRNA network, has been previously associated with gastric cancer ([@b32-ol-0-0-10852]). High expression of OPCML-IT1 may compete with seven key DEmiRNAs (mir-372, mir-373, mir-519d, mir-184, mir-205, mir-506 and mir-375) to mediate the expression of target genes. Furthermore, similar to MIR181A2HG, survival analysis revealed that increased expression of OPCML-IT1 was associated with a poor prognosis for patients with CCA. Based on the results of pathways analysis in the current study, knockdown of MIR181A2HG and OPCML-IT1 may prevent cell proliferation in CCA and prolong survival time of patients with CCA. miRNAs are master regulators of fine-tuning gene expression in a number of pathways, including cell cycle pathways ([@b33-ol-0-0-10852]). The current study demonstrated that 12 DEmiRNAs were involved in the ceRNA network, two of which (mir-144 and mir-184) were associated with differences in the overall survival time of patients with CCA. A previous study revealed that mir-144 may be an essential suppresser of CCA cell proliferation and invasion by targeting platelet activating factor acetylhydrolase 1b regulatory subunit 1 ([@b34-ol-0-0-10852]). The survival analysis of mir-144 performed in the current study demonstrated that low expression of mir-144 can prolong patient survival. While mir-184 was revealed to be a target gene in breast ([@b35-ol-0-0-10852]) and liver ([@b32-ol-0-0-10852]) cancer, few studies have investigated the role of mir-184 in CCA ([@b35-ol-0-0-10852],[@b36-ol-0-0-10852]). Survival analysis indicated that high expression of mir-184 was associated with poor prognosis in patients with CCA. Thus, the mechanism of mir-184 in CCA requires further investigation.

Based on the results of WGCNA performed in the current study, two protein-coding genes involved in the ceRNA network from four modules were identified, of which SALL3 and E2F1 were demonstrated to affect the overall survival time of patients with CCA. Epigenetic silencing of SALL3 was a predictor of poor survival in head and neck cancer ([@b37-ol-0-0-10852]). E2F1 is involved in the control of the cell cycle, proliferation and cell death ([@b38-ol-0-0-10852]). E2F1 was demonstrated to affect the overall survival in patients with prostate ([@b39-ol-0-0-10852]) and colorectal cancer ([@b40-ol-0-0-10852]). In the construction of ceRNA network, SALL3 or E2F1 can be a direct target of the hub DEmiRNA, mir-519d. Therefore, this DEmiRNA may compete with DElncRNA OPCML-IT1. Furthermore, the results of the regression analysis indicated a stronger correlation between SALL3 and OPCML-IT1 than between E2F1 and OPCML-IT1. Consequently, OPCML-IT1 may exhibit tumor-suppressing effects in CCA.

The current study had certain advantages over a previously published study ([@b28-ol-0-0-10852]): i) WGCNA was used to confirm the hub genes in functional modules; ii) the survival analysis of genes instead of clusters was investigated, which provided a clearer direction for future research; and iii) Pearson\'s correlation analysis was performed to validate the correlations between DElncRNAs and DEmRNAs involved in the formulated ceRNA network. Due to the several differences in the types of RNA-Seq gene expression, methods used for gene selection and cut-off criteria used for analyzing DEGs, there was no overlap between the current study and a previous study by Wan *et al* ([@b28-ol-0-0-10852]). The current study demonstrated the importance of SALL3 and OPCML-IT1 expression in patients with CCA, based on analysis of a weighted gene co-expression network, a ceRNA network and patient overall survival time. Future studies are required to verify the involvement of the ceRNA network in CCA.
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![Protein-protein network visualization of different color modules by weighted gene co-expression network analysis. Each rounded rectangle corresponds to a protein-coding gene, while the yellow color indicated the key differentially expressed mRNAs at the core of modules.](ol-18-05-5283-g01){#f2-ol-0-0-10852}

![Identified competing endogenous RNA network in cholangiocarcinoma. The diamond, rounded rectangle and circle present long non-coding RNAs, microRNAs and mRNAs, respectively. Blue indicates downregulation while red indicates upregulation.](ol-18-05-5283-g02){#f3-ol-0-0-10852}
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![Pearson\'s correlation coefficient analysis between the expression levels of OPCML-IT1 and SALL3 in the competing endogenous RNA network. SALL3, spalt like transcription factor; OPCML-IT1, OPCML intronic transcript 1; TPM, transcripts per million.](ol-18-05-5283-g04){#f5-ol-0-0-10852}

###### 

Clinical characteristics of the 36 patients with cholangiocarcinoma.

  Variables                                 Patient characteristics
  ----------------------------------------- -------------------------
  Age, mean years ± SD                      63.48±12.85
  Overall survival time, mean months ± SD   25.49±18.56
  Sex, n (%)                                
    Male                                    16 (44.4)
    Female                                  20 (55.6)
  Ethnicity, n (%)                          
    Caucasian                               31 (86.2)
    Asian                                   3 (8.3)
    African American                        2 (5.5)
  Tumor stage, n (%)                        
    Stage I                                 19 (52.7)
    Stage II                                9 (25.0)
    Stage III                               1 (2.8)
    Stage IV                                2 (5.6)
    Stage IVa                               2 (5.6)
    Stage IVb                               3 (8.3)
  Alive, n (%)                              
    Yes                                     18 (50.0)
    No                                      18 (50.0)

###### 

KEGG pathway analysis of weighted gene co-expression network analysis modules.

  A, Turquoise                                                                                                              
  --------------------------------------------------------------------------- ------------------ -------------------------- -------------
  'Regulation of signaling'                                                   76                 SHISA6, PCDHA1, SALL3,     8.5×10^−05^
  'Regulation of cell communication'                                          73                 CYP1B1, SERPINA1, TIMP1,   3.2×10^−04^
  'Regulation of multicellular organismal process'                            68                 CD177, PRSS3               4.6×10^−05^
  'Anatomical structure morphogenesis'                                        59                                            1.8×10^−04^
  'Tissue development'                                                        47                                            9.2×10^−04^
  'Secretion'                                                                 46                                            8.0×10^−05^
  'Cell-cell signaling'                                                       45                                            8.5×10^−05^
  'Secretion by cell'                                                         45                                            4.6×10^−05^
  'Positive regulation of cell communication'                                 43                                            8.6×10^−04^
  'Positive regulation of multicellular organismal process'                   41                                            7.9×10^−04^
  'Neuron differentiation'                                                    35                                            9.2×10^−04^
  'Regulation of secretion'                                                   25                                            9.2×10^−04^
  'Regulation of secretion by cell'                                           24                                            9.2×10^−04^
  'Epidermis development'                                                     19                                            1.3×10^−03^
                                                                                                                            
  **B, Blue**                                                                                                               
                                                                                                                            
  **KEGG pathway**                                                            **Input number**   **Top genes**              **P-value**
                                                                                                                            
  'Cellular developmental process'                                            93                 GRIK3, E2F1, PCDHAC2,      6.4×10^−08^
  'System development'                                                        92                 MMP3, PAX7, S100B          4.1×10^−06^
  'Cell differentiation'                                                      91                                            6.4×10^−08^
  'Anatomical structure morphogenesis'                                        53                                            9.9×10^−04^
  'Response to external stimulus'                                             48                                            9.9×10^−04^
  'Tissue development'                                                        46                                            3.7×10^−04^
  'Cell adhesion'                                                             38                                            2.2×10^−04^
  'Chemotaxis'                                                                22                                            2.2×10^−04^
  'Extracellular structure organization'                                      22                                            1.1×10^−06^
  'Extracellular matrix organization'                                         21                                            4.0×10^−07^
  'Cell chemotaxis'                                                           14                                            6.6×10^−04^
  'Collagen metabolic process'                                                12                                            4.1×10^−06^
  'Collagen catabolic process'                                                10                                            4.1×10^−06^
                                                                                                                            
  **C, Brown**                                                                                                              
                                                                                                                            
  **KEGG pathway**                                                            **Input number**   **Top genes**              **P-value**
                                                                                                                            
  'Nervous system development'                                                49                 FOXQ1, HOXC13, TMEM100,    7.2×10^−04^
  'Cell-cell signaling'                                                       43                 PAX7, COL13A1, NPHS1,      8.6×10^−05^
  'Transmembrane transport'                                                   41                 MXRA8                      1.5×10^−04^
  'Behavior'                                                                  24                                            6.1×10^−05^
  'Chemical synaptic transmission'                                            23                                            1.5×10^−04^
  'Ossification'                                                              16                                            6.3×10^−04^
  'Learning or memory'                                                        15                                            8.6×10^−05^
  'Neurotransmitter transport'                                                13                                            5.9×10^−04^
  'Memory'                                                                      9                                           5.9×10^−04^
  'Hippocampus development'                                                     8                                           4.0×10^−04^
  'Positive regulation of fat cell proliferation'                               3                                           7.0×10^−04^
                                                                                                                            
  **D, Yellow**                                                                                                             
                                                                                                                            
  **KEGG pathways**                                                           **Input number**   **Top genes**              **P-value**
                                                                                                                            
  'Cell morphogenesis'                                                          7                TBC1D2, LRRK2              9.9×10^−03^
  'Cell part morphogenesis'                                                     6                                           9.4×10^−03^
  'Tangential migration from the subventricular zone to the olfactory bulb'     2                                           9.4×10^−03^

KEGG, Kyoto Encyclopedia of Genes and Genomes; SHISA6, shisa family member 6; PCDHA1, protocadherin α 1; SALL3, spalt like transcription factor 3; CYP1B1, cytochrome P450 family 1 subfamily B member 1; SERPINA1, serpin family A member 1; TIMP1, TIMP metallopeptidase inhibitor 1; CD177, CD177 molecule; PRSS3, serine protease 3; GRIK3, glutamate ionotropic receptor kainate type subunit 3; E2F1, E2F transcription factor 1; PCDHAC2, protocadherin α subfamily C, 2; MMP3, matrix metallopeptidase 3; PAX7, paired box 7; S100B, S100 calcium binding protein B; FOXQ1, forkhead box Q1; HOXC13, homeobox C13; TMEM100, transmembrane protein 100; COL13A1, collagen type XIII α 1 chain; NPHS1, NPHS1 adhesion molecule, nephrin; MXRA8, matrix remodeling associated 8; TBC1D2, TBC1 domain family member 2; LRRK2, leucine rich repeat kinase 2.

###### 

Thirty DElncRNAs interact with the 12 DEmiRNAs as retrieved from the miRcode database.

  lncRNA       miRNAs
  ------------ -----------------------------------------
  IGF2-AS      hsa-mir-519d
  LINC00302    hsa-mir-31, hsa-mir-506
  AC022148.1   hsa-mir-372, hsa-mir-373, hsa-mir-144,
               hsa-mir-519d, hsa-mir-205, hsa-mir-221,
               hsa-mir-222, hsa-mir-31
  LINC00313    hsa-mir-372, hsa-mir-373, hsa-mir-187,
               hsa-mir-205, hsa-mir-31, hsa-mir-375
  AC004832.1   hsa-mir-519d, hsa-mir-31,
  AC002511.1   hsa-mir-519d
  AC006305.1   hsa-mir-519d, hsa-mir-221, hsa-mir-222,
               hsa-mir-506, hsa-mir-375
  AP000525.1   hsa-mir-31
  UCA1         hsa-mir-184, hsa-mir-506
  AC010336.2   hsa-mir-372, hsa-mir-373, hsa-mir-144,
               hsa-mir-519d, hsa-mir-205, hsa-mir-31
  CLDN10-AS1   hsa-mir-221, hsa-mir-222
  MIR181A2HG   hsa-mir-205
  LINC00365    hsa-mir-519d
  LINC00457    hsa-mir-144
  SFTA1P       hsa-mir-221, hsa-mir-222
  LINC00423    hsa-mir-31
  HOTAIR       hsa-mir-519d, hsa-mir-221, hsa-mir-222,
               hsa-mir-506, hsa-mir-375
  HCG22        hsa-mir-31, hsa-mir-506
  MIR4500HG    hsa-mir-144, hsa-mir-31
  MIR205HG     hsa-mir-205, hsa-mir-221, hsa-mir-222,
               hsa-mir-31, hsa-mir-506
  CYP1B1-AS1   hsa-mir-205
  LINC00460    hsa-mir-222, hsa-mir-221
  LINC00284    hsa-mir-519d, hsa-mir-205, hsa-mir-506
  AC068594.1   hsa-mir-222, hsa-mir-221
  AC011383.1   hsa-mir-31
  SYNPR-AS1    hsa-mir-375
  GDNF-AS1     hsa-mir-187
  OPCML-IT1    hsa-mir-372, hsa-mir-373, hsa-mir-519d,
               hsa-mir-184, hsa-mir-205, hsa-mir-506,
               hsa-mir-375,
  AC110619.1   hsa-mir-184
  AP001029.2   hsa-mir-31

DE, differentially expressed; lncRNA, long non-coding RNA; miRNA, microRNA.

###### 

Specific miRNAs, lncRNAs and mRNAs in the competing endogenous RNA network.

  A, miRNA                                                                           
  ----------------- ----------------- ----------------------- ---------------------- -------------
  hsa-mir-519d      ENSG00000207981   Up                      4.74                   3.73E-06
  hsa-mir-31        ENSG00000199177   Up                      2.45                   8.69E-20
  hsa-mir-506       ENSG00000207731   Up                      2.03                   7.24E-13
  hsa-mir-372       ENSG00000199095   Up                      3.46                   4.82E-09
  hsa-mir-373       ENSG00000199143   Up                      2.55                   3.35E-05
  hsa-mir-144       ENSG00000283819   Down                    −2.14                  1.80E-48
  hsa-mir-205       ENSG00000284485   Up                      2.08                   1.12E-07
  hsa-mir-221       ENSG00000207870   Up                      3.36                   1.92E-60
  hsa-mir-222       ENSG00000207725   Up                      3.02                   9.01E-57
  hsa-mir-187       ENSG00000207797   Up                      3.17                   8.72E-20
  hsa-mir-375       ENSG00000198973   Up                      2.89                   1.10E-23
  hsa-mir-184       ENSG00000207695   Up                      3.62                   6.05E-12
                                                                                     
  **B, lncRNA**                                                                      
                                                                                     
  **Gene symbol**   **Gene ID**       **Expression change**   **log2 fold change**   **P-value**
                                                                                     
  IGF2-AS           ENSG00000099869   Up                      3.94                   7.11E-08
  LINC00302         ENSG00000176075   Up                      3.36                   8.92E-08
  AC022148.1        ENSG00000180458   Up                      3.13                   3.85E-28
  LINC00313         ENSG00000185186   Up                      2.16                   1.53E-11
  AC004832.1        ENSG00000181123   Down                    −2.19                  3.22E-20
  AC002511.1        ENSG00000232680   Down                    −2.29                  7.96E-30
  AC006305.1        ENSG00000206129   Down                    −2.62                  2.57E-42
  AP000525.1        ENSG00000272872   Up                      2.52                   5.41E-17
  UCA1              ENSG00000214049   Up                      3.48                   6.85E-12
  AC010336.2        ENSG00000260500   Up                      2.33                   2.16E-28
  CLDN10-AS1        ENSG00000223392   Up                      4.19                   1.58E-13
  MIR181A2HG        ENSG00000224020   Up                      2.12                   2.23E-41
  LINC00365         ENSG00000224511   Up                      2.39                   5.59E-14
  LINC00457         ENSG00000225179   Up                      2.87                   6.46E-12
  SFTA1P            ENSG00000225383   Up                      2.19                   3.09E-19
  LINC00423         ENSG00000226968   Up                      3.17                   4.16E-21
  HOTAIR            ENSG00000228630   Up                      2.41                   2.64E-06
  HCG22             ENSG00000228789   Up                      2.76                   3.18E-19
  MIR4500HG         ENSG00000228824   Down                    −2.48                  7.14E-21
  MIR205HG          ENSG00000230937   Up                      2.63                   6.43E-10
  CYP1B1-AS1        ENSG00000232973   Up                      2.26                   9.22E-35
  LINC00460         ENSG00000233532   Up                      3.61                   3.66E-20
  LINC00284         ENSG00000233725   Up                      3.91                   8.27E-30
  AC068594.1        ENSG00000263718   Up                      2.65                   1.38E-37
  AC011383.1        ENSG00000253852   Up                      2.37                   1.86E-26
  SYNPR-AS1         ENSG00000241359   Up                      2.66                   4.38E-07
  GDNF-AS1          ENSG00000248587   Up                      3.59                   1.08E-12
  OPCML-IT1         ENSG00000254896   Up                      5.02                   5.08E-14
  AC110619.1        ENSG00000218416   Up                      2.09                   2.36E-22
  AP001029.2        ENSG00000267199   Up                      2.69                   1.10E-35
                                                                                     
  **C, mRNA**                                                                        
                                                                                     
  **Gene symbol**   **Gene ID**       **Expression change**   **log2 fold change**   **P-value**
                                                                                     
  LRRK2             ENSG00000188906   Up                      4.02                   7.71E-51
  TBC1D2            ENSG00000095383   Up                      2.01                   7.90E-42
  E2F1              ENSG00000101412   Up                      2.01                   7.55E-40
  SHISA6            ENSG00000188803   Up                      3.91                   6.01E-28
  CYP1B1            ENSG00000138061   Up                      3.09                   1.35E-24
  TMEM100           ENSG00000166292   Up                      2.82                   2.19E-20
  PCDHAC2           ENSG00000243232   Up                      2.16                   2.48E-20
  GRIK3             ENSG00000163873   Up                      2.84                   1.52E-19
  FOXQ1             ENSG00000164379   Up                      2.10                   1.94E-19
  PCDHA1            ENSG00000204970   Up                      2.03                   1.02E-13
  HOXC13            ENSG00000123364   Up                      2.94                   1.53E-07
  SALL3             ENSG00000256463   Up                      2.52                   6.15E-06

miRNA, micro RNA; lncRNA, long non-coding RNA.
